- GSK shares fell on Wednesday despite better-than-expected Q3 results, as investors reacted to weaker vaccine sales and restructuring charges.
- Pre-tax profit fell 19% to £1.9bn in the July to September quarter, with £318m of restructuring charges.
- Investors also weighed the company's overall outlook and the looming patent loss for a blockbuster HIV drug.
- FiercePharma reported on Oct 23, 2026 that GSK received FDA approval for Jemperli in certain rectal cancer patients and a landmark approval for Hibsago in chronic hepatitis B.
Quotes
“reported a 19% decline in pre-tax profit to £1.9bn in the July to September quarter”
Sources
- GSK shares dive as weaker sales and mounting costs unnerve investorsThe Guardian
- <a href="https://www.fiercepharma.com/pharma/gsks-double-fda-win-roches-15b-deal-and-rise-point-care-marketing" hreflang="en">GSK's double FDA win, Roche's $15B deal and the rise of point-of-care marketing</a>FiercePharma